Trending News – July 22, 2021

In this minisode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including: the Biden administration’s interim final rule banning surprise billing (00:35), Walmart’s launch of a private band insulin analog (04:21), and interim trial results for in vivo CRISPR-based genome editing candidate NTLA-2001 (07:00).

Podcast Tags: surprise billing, health insurance, diabetes, drug prices, gene therapy, CRISPR, healthcare, healthcare news

Source Links:

· https://www.fiercehealthcare.com/payer/biden-admin-releases-first-interim-final-rule-to-ban-surprise-medical-bills

· https://www.beckershospitalreview.com/finance/cms-unveils-surprise-billing-rule-10-things-to-know

· https://www.fiercehealthcare.com/finance/walmart-teams-novo-nordisk-to-launch-private-band-analog-insulin

· https://www.statnews.com/pharmalot/2021/06/29/walmart-insulin-novo-nordisk-diabetes

· https://www.fiercebiotech.com/biotech/first-human-trial-results-intellia-shows-world-gene-editing-has-arrived

· https://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Mindy McGrath, Healthcare Industry Learning Lead

[email protected]

Ryan Hummel, Executive and Head of Provider Sector